Jeffrey Hung
Stock Analyst at Morgan Stanley
(2.28)
# 2,668
Out of 4,915 analysts
211
Total ratings
38.21%
Success rate
-0.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $166 → $165 | $115.77 | +42.52% | 7 | Jul 22, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $148 → $150 | $135.83 | +10.43% | 27 | Jul 22, 2025 | |
| FOLD Amicus Therapeutics | Upgrades: Overweight | $102 → $108 | $6.13 | +1,661.83% | 5 | Jul 17, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $65 → $55 | $27.25 | +101.83% | 9 | Jul 14, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $52 → $56 | $26.35 | +112.52% | 4 | Jun 17, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Equal-Weight | $20 → $24 | $23.33 | +2.87% | 25 | May 20, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Overweight | $25 → $20 | $5.71 | +250.26% | 3 | May 19, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Equal-Weight | $15 → $17 | $8.52 | +99.53% | 5 | May 6, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $37 → $34 | $3.56 | +855.06% | 3 | Mar 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Assumes: Overweight | $72 | $84.26 | -14.55% | 11 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $67 → $70 | $50.50 | +38.61% | 11 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $4 | $1.56 | +157.23% | 3 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $59.32 | +43.29% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $38 → $35 | $7.93 | +341.36% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $16.69 | +61.82% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $4.36 | +14.81% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $35.75 | +87.41% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.45 | +314.20% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $29.09 | +140.63% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $0.88 | +354.70% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $13 → $4 | $8.04 | -50.25% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $0.77 | +419.48% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $3.42 | +309.36% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $2.91 | +72.12% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $1.41 | +112.77% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.50 | +833.33% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $3.29 | +204.15% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $37.12 | -40.73% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $15.18 | +878.26% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.85 | +3,143.24% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.42 | +75.44% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $5.11 | +12,581.02% | 6 | May 8, 2020 |
Jazz Pharmaceuticals
Jul 22, 2025
Maintains: Overweight
Price Target: $166 → $165
Current: $115.77
Upside: +42.52%
Neurocrine Biosciences
Jul 22, 2025
Maintains: Overweight
Price Target: $148 → $150
Current: $135.83
Upside: +10.43%
Amicus Therapeutics
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $6.13
Upside: +1,661.83%
Ultragenyx Pharmaceutical
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $27.25
Upside: +101.83%
CG Oncology
Jun 17, 2025
Maintains: Overweight
Price Target: $52 → $56
Current: $26.35
Upside: +112.52%
ACADIA Pharmaceuticals
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $23.33
Upside: +2.87%
Contineum Therapeutics
May 19, 2025
Maintains: Overweight
Price Target: $25 → $20
Current: $5.71
Upside: +250.26%
Bicycle Therapeutics
May 6, 2025
Maintains: Equal-Weight
Price Target: $15 → $17
Current: $8.52
Upside: +99.53%
enGene Holdings
Mar 11, 2025
Maintains: Overweight
Price Target: $37 → $34
Current: $3.56
Upside: +855.06%
Rhythm Pharmaceuticals
Mar 7, 2025
Assumes: Overweight
Price Target: $72
Current: $84.26
Upside: -14.55%
Mar 7, 2025
Assumes: Overweight
Price Target: $67 → $70
Current: $50.50
Upside: +38.61%
Mar 7, 2025
Assumes: Overweight
Price Target: $4
Current: $1.56
Upside: +157.23%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $59.32
Upside: +43.29%
Mar 7, 2025
Assumes: Overweight
Price Target: $38 → $35
Current: $7.93
Upside: +341.36%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $16.69
Upside: +61.82%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $4.36
Upside: +14.81%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $35.75
Upside: +87.41%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $8.45
Upside: +314.20%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $29.09
Upside: +140.63%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $0.88
Upside: +354.70%
Dec 19, 2023
Downgrades: Underweight
Price Target: $13 → $4
Current: $8.04
Upside: -50.25%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $0.77
Upside: +419.48%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $3.42
Upside: +309.36%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $2.91
Upside: +72.12%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $1.41
Upside: +112.77%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.50
Upside: +833.33%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $3.29
Upside: +204.15%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $37.12
Upside: -40.73%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $15.18
Upside: +878.26%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.85
Upside: +3,143.24%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.42
Upside: +75.44%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $5.11
Upside: +12,581.02%